SINOPHARM (01099) announced that its subsidiary, China National Medical Device Co., Ltd., recorded annual revenue of RMB 74.89 billion for the year ended December 31, 2025, representing a decrease of 2.35% compared to the previous year. Operating profit reached RMB 1.25 billion, an increase of 2.38% year-on-year. Comprehensive income attributable to owners of the parent company amounted to RMB 507 million, marking a growth of 25.64% compared to the prior year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.